C-erbB-2 oncoprotein expression in operable non-small cell lung cancer

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 987-994

  Giatromanolaki, Alexandra ^a   Gorgoulis, Vassilios ^c   Chetty, Ranjan ^a   Koukourakis, Michael I ^b,d   Whitehouse, Ruth ^b   Kittas, Christos ^c   Veslemes, Marinos ^c   Gatter, Kevin C ^a   Iordanoglou, Ioannis ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

C erbB 2; Lung cancer; Prognosis

Indexed keywords

ONCOPROTEIN;

ARTICLE; CANCER STAGING; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0029982436     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of human c-erbB-2 gene: a 105-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986.
2. Horak E, Smith K, Bromley L, LeJeune Greenaill M, Lane D, Harris AL: Mutant p53. EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-2284, 1991.
3. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CHW, Neal DE: Expression of mutant p53, c-erbB-2 and epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63: 967-970, 1991.
4. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372-1375, 1991.
5. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3: 109-113, 1994.
6. Kern JA, Slebos RJC, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D: C-erbB-2 expression and codon 12 K-ras mutationsboth predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516-520, 1994.
7. Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S, Hatakenaka R, Matsubara Y, Funatsu T: Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2, and correlation with prognosis in 143 cases of resected lung cancer. Gan-To -Kagaku-Ryoho 20: 82 4-827, 1993.
8. Mountain CF: A new international staging system for lung cancer. Chest 89(Suppl): 225-233, 1986.
9. Corbett IP, Henry JA, Angus B et al: NCL-CB 11, a new monoclonal antibody recognising the internal domain of the c-erbB-2 oncogene protein effective for use on formaline fixed, paraffin embedded tissue. J Pathol 161: 15-25, 1970.
10. Kay EW, Barry Walsh CJ, Curran B, Leader M: C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 47: 16-822, 1994.
11. Delellis RA, Sternberger LA, Mann RB, Banks PM, Nakane PK: Immunoperoxidase technics in diagnostic pathology. Am J Clin Pathol 77:483-488, 1979.
12. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 6: 735-738, 1992.
13. Tungekar MF, Gatter KC, Dunnill M, Mason DY: Ki67 immunostaining and survival in operable lung cancer. Histopathology 19: 545-550, 1991.
14. Arnaout AH, Dawson PM, Soomro S, Taylor P, Theodorou NA: Feldmann M, Fendly BM, Shepard HM, Shousha S: Her-2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immuno-histochemical study using three different antibodies. J Clin Pathol 45: 726-727, 1492.
15. Coombs LM, Piggott DA, Sweeney E. Proctor AJ, Aydmann ME, Parkinson C, Knowles MA: Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63: 601-608, 1991.
16. Kerns BM, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfie'd LJ: Assessing c-erbB-2 amplification by immunohistochemistry in paraffin embeded breast cancer. Mod Path 6: 673-678, 1993.
17. Harpole DH, Hendon JE, Wolfe WG, Iglehart JD, Marks JR: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 55: 51-56, 1995.
18. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y: Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 44: 802-805, 1993.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of Her-2 /neu oncogene. Science 235: 177-182, 1987.
20. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovascularisation to metastasis of non small cell lung cancer. Lancet 340: 145-146, 1992.
21. Giatromanolaki A, Koukourakis M, O Byrne K, Fox S, Whitehouse R, Talbot D, Harris AL, Gatter KC: Angiogenesis is a significant prognostic marker in operable non-small cell lung cancer. J Pathol (in press), 1995.
22. Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine S, Angeleti CA, Harris AL, Bevilacqua G: Microvessel count predict metastatic disease and survival in non-small cell lung cancer. J Pathol 177: 57-63, 1995.